4 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 3 Phase 1, 3 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 3 | Completed 2, Recruiting 1 |
| Early Phase 1 | 1 | Active not recruiting 1 |
Follow quisinostat: new trials by email Literature Review of quisinostat trials Research Report on quisinostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype Glioblastomas Quisinostat - Glioblastoma WHO Grade IV | Early Phase 1 | Active not recruiting | Nader Sanai | 30 | 2025-09-04 | 2026-03-17 |
| Adjuvant Quisinostat in High-Risk Uveal Melanoma Quisinostat - Uveal Melanoma | Phase 2 | Recruiting | University of Miami | 63 | 2025-05-27 | 2026-06-18 |
| Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy Quisinostat, Paclitaxel, Carboplatin - Ovarian Cancer | Phase 2 | Completed | NewVac LLC | 31 | 2015-09-01 | 2018-06-27 |
| Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy Quisinostat, Paclitaxel, Carboplatin - Non-small Cell Lung Cancer, Epithelial Ovarian Cancer | Phase 1 | Completed | NewVac LLC | 51 | 2013-08-01 | 2016-05-03 |
| A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma Quisinostat, 12 mg - Lymphoma, T-Cell, Cutaneous | Phase 2 | Completed | Janssen Research & Development, LLC | 26 | 2011-11-01 | 2016-11-03 |
| A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Leukemia or Myelodysplastic Syndrome JNJ-26481585 - Advanced or Refractory Leukemia, Myelodysplastic Syndromes | Phase 1 | Terminated | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 10 | 2008-12-01 | 2012-09-14 |
| A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced Solid Malignancies and Lymphoma. JNJ-26481585 - Lymphoma, Neoplasms | Phase 1 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 92 | 2007-08-01 | 2012-09-17 |
Lymphoma (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Leukemia (1) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Cutaneous (1) · Myelodysplastic Syndromes (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Uveal Melanoma (1)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2) · NewVac LLC (2) · Janssen Research & Development, LLC (1) · Nader Sanai (1) · University of Miami (1)
United States (4) · Russia (2) · United Kingdom (2) · France (1) · Germany (1) · Portugal (1) · Spain (1)
Jose Lutzky, MD (1) · Nader Sanai, MD (1) · Sergei A. Tjulandin, Prof. (1) · Sergey Tjulandin, Prof (1)